文献速递白血病造血干细胞移植与细胞治疗

CXCR4阻断通过同种异体淋巴细胞输注提高白血病清除效果

CXCR4 blockade improves leukemia eradication by allogeneic lymphocyte infusion.
PubMed 文献 · Am J Hematol · 2018-04-16

该研究利用携带源自过表达MLL-AF9的人造血干细胞的原发性人急性淋巴细胞白血病的小鼠模型,发现同种异体淋巴细胞输注(ALI)介导的移植物抗白血病效应选择性遗漏骨髓中的白血病细胞。骨髓中白血病细胞对ALI的抵抗源于组织的免疫抑制状态,用CXCR4拮抗剂AMD3100将白血病细胞从骨髓中动员出来后,ALI的完全缓解率显著提高。过继转移实验证实,与仅接受ALI的受体相比,接受ALI联合AMD3100治疗的受体骨髓中白血病起始细胞频率显著降低。

要点

  • ALI介导的移植物抗白血病效应选择性遗漏骨髓中的白血病细胞。
  • AMD3100将白血病细胞从骨髓动员后,ALI的完全缓解率显著提高。
  • ALI联合AMD3100组骨髓白血病起始细胞频率较单用ALI组显著降低。

核心结论

  • 骨髓的免疫豁免特性在很大程度上导致了免疫治疗后的复发。
  • AMD3100治疗可能提供一种临床实用的方法来改善过继性同种异体细胞治疗的结局。

研究设计与样本

  • 研究使用携带源自过表达MLL-AF9的人造血干细胞的原发性人急性淋巴细胞白血病的小鼠模型。
  • 研究进行了过继转移实验。

主要发现

  • ALI介导的移植物抗白血病效应选择性遗漏骨髓中的白血病细胞。
  • 骨髓中白血病细胞对ALI的抵抗源于组织的免疫抑制状态。
  • 用CXCR4拮抗剂AMD3100将白血病细胞从骨髓动员后,ALI的完全缓解率显著提高。
  • 过继转移实验证实,与仅接受ALI的受体相比,接受ALI联合AMD3100治疗的受体骨髓中白血病起始细胞频率显著降低。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Persistent low levels of disease in bone marrow, an immunoprivileged tissue, are responsible for relapse following allogeneic hematopoietic cell transplantation. Using mouse models carrying primary human acute lymphoblast leukemia derived from MLL-AF9-overexpressing human hematopoietic stem cells, we demonstrate that allogeneic lymphocyte infusion (ALI)-mediated graft-vs.-leukemia effects selectively spare leukemia cells in the bone marrow. The resistance of leukemia cells to ALI within bone marrow is due to the immunosuppressive status of the tissue, as ALI achieved a significantly increased complete remission rate when leukemia cells were dislodged from bone marrow by treatment with a CXCR4 antagonist AMD3100. Adoptive transfer experiments confirmed that the frequency of leukemia-initiating cells in bone marrow was significantly decreased in the recipients treated with ALI plus AMD3100 compared to those receiving ALI only. These findings indicate that the immunoprivileged nature of bone marrow is largely responsible for relapse after immunotherapies, and that treatment with AMD3100 may offer a clinically-practical approach to improving the outcome of adoptive allogeneic cell therapy.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Jin CH, Li Y, Xia J, et al. CXCR4 blockade improves leukemia eradication by allogeneic lymphocyte infusion. Am J Hematol. 2018. PMID: 29603337. doi:10.1002/ajh.25099

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。